CD274 and neoplasm: To develop an integrative, CGP + qTP based tumor-agnostic PD-(L)1 blockade predictive biomarker, we first limited results to the 648 of 9899 (6.5%) patients in the SCMD who met all of the inclusion/exclusion criteria (see Methods) including: valid TMB measurements from StrataNGS testing (including meeting the overall 20% tumor content requirement), valid immune gene expression quantification from an investigative multiplex PCR based qTP test, and with a pembrolizumab containing systemic line of therapy (Fig. S1).